StreetSmart Live! Presents Metallic Group of Companies on 01/26/2021. Learn More

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients

  ()
AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. read more >

Imagin Medical Is Bringing Cystoscopy into the 21st Century

Contributed Opinion
  ()
Dr. KSS, MD, PhD, editor-in-chief of PubBio.co, profiles a small cap that "is poised to bring to clinic a next-generation of must-have cystoscopy equipment." read more >
News Update

Healthcare Tech Firm Announces New Multilingual IVR Product

News Update
  ()
Reliq Health Technologies launched a multilingual interactive voice recognition product called iUGO Care IVR and has contracted with a Maryland physician practice to offer the service to patients speaking Russian and English. read more >

A Solace to the Stress of the SolarWinds Hack

Contributed Opinion
  ()
Against the backdrop of the massive SolarWinds hack, value investor Jack Hurley discusses his investment thesis for Leonovus Inc, whose products provide an "ironclad level of cybersecurity." read more >

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine

  ()
Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2. read more >
News Update

Biotech Given Go-Ahead to Proceed with Phase 3 COVID-19 Study

News Update
  ()
Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2. read more >
News Update

Life Sciences Firm Partners with University to Develop Biosynthetic Psilocybin

News Update
  ()
Revive Therapeutics entered into a research agreement with North Carolina State University to develop psilocybin utilizing a natural biosynthesis enzymatic platform. read more >

Aclaris Shares Triple in Value on Positive Topline Data from Phase 2a Rheumatoid Arthritis Trial

  ()
Shares of Aclaris Therapeutics Inc. soared to a new 52-week high after the company reported positive preliminary topline data from its Phase 2a trial of oral ATI-450 for moderate to severe rheumatoid arthritis. read more >

Avinger Shares Rise 40% on Launch of Image-Guided Device to Diagnose and Treat PAD

  ()
Shares of Avinger Inc. reached a new 52-week high after the company reported it initiated a full commercial launch of its Tigereye™ Image-Guided CTO Crossing Catheter system for diagnosing and treating peripheral artery disease. read more >
News Update

Neurosciences Firm Outlines Strategic Priorities for 2021

News Update
  ()
ProMIS Neurosciences discusses its four priority areas in 2021. read more >

Inari Shares Flow 14% Higher on Triple Digit YoY Growth in Procedures and Revenues

  ()
Shares of Inari Medical Inc. established a new 52-week high after the company reported that preliminary revenue in Q4/20 increased year-over-year by greater than 140%. read more >

As Psychedelics Move Mainstream, Small Cap Positions Itself at the Center of the Industry

  ()
Two year old DELIC Corp. has gotten in on the ground floor of the nascent psychedelic sector. read more >

A Novel, First-in-Class Blood Clotting Agent Takes Shape as a Bloody Compelling Investment

Contributed Opinion
  ()
Private start-up RxMP's safe way to stop bleeding inexpensively is already the envy of bigger players, states Dr. KSS, MD, PhD, editor-in-chief of PubBio.co. Can it go the distance through proof of concept? read more >

Expert Investing Ideas

"AGN [shares] are now in a vigorous uptrend."

–Clive Maund, CliveMaund.com


"SPR is the number one cannabis stock to own today."

–Cynthia Berryman, Financial News Now



Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Mesoblast Reports Phase 3 Trial Data Showing Substantial Reductions in Cardiac and Stroke Events in CHF Patients

  ()
Shares of Mesoblast Ltd. traded 36% higher after the company reported positive results from its Phase 3 DREAM-HF study showing that a single dose of rexlemestrocel-L provided very significant decreases in heart attacks, strokes and cardiac death in patients diagnosed with chronic heart failure. read more >
News Update

Pharma Developer Outlines 2021 Clinical Program Initiatives

News Update
  ()
Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials. read more >

Chimerix Expands Late-Stage Oncology Pipeline Through $78M Oncoceutics Acquisition

  ()
Chimerix Inc. shares traded 65% higher after the company reported it entered into an agreement to acquire Oncoceutics Inc. in a combination stock and cash deal valued at $78 million plus milestone incentives totaling up to $360 million. read more >